Biotech
AI Revolutionizes Cancer Diagnosis with $16M Investment
OneCell Diagnostics, a pioneering healthcare startup, has secured $16 million in funding to enhance its innovative cancer diagnosis and monitoring...
Read more
Global Health Crisis: The Soaring Cost of Cancer Treatment
The world is facing a growing health crisis as cancer drug costs continue to skyrocket, rendering treatment unaffordable for millions....
Read more
Halozyme’s Bold Move into Integrated Biopharmaceutical Solutions
Halozyme Therapeutics has made a significant move to expand its portfolio beyond its proprietary delivery technology, offering $2 billion to...
Read more
BioNTech Seals $800M Deal to Acquire Potential Keytruda Rival
In a strategic move to bolster its oncology pipeline, German biotechnology company BioNTech has acquired an innovative cancer therapy from...
Read more
Hidden Data on Obesity Drug Sends Amgen’s Market Value Plummeting by $12 Billion
In a stunning reversal of fortune, biotechnology giant Amgen Inc. suffered a staggering $12 billion loss in market capitalization after...
Read more
FDA Deals Another Blow to Kezar’s Zetomipzomib Program
The US Food and Drug Administration (FDA) has placed a second clinical hold on Kezar Life Sciences' zetomipzomib program in...
Read more
Novartis Signs $150M Deal with Schrödinger to Advance Drug Discovery Programs
Pharmaceutical giant Novartis has entered a strategic partnership with Schrödinger, paying $150 million for access to the company's innovative drug...
Read more
NetOne Unveils $1-a-Month Healthcare Plan in Zimbabwe, Targeting Affordable Coverage for All
In a bold move to address Zimbabwe's healthcare affordability crisis, telecommunications provider NetOne has launched a $1-per-month healthcare plan called...
Read more
CMS Grants Medicare Coverage to Medtronic and Recor Medical Renal Denervation Systems
In a significant win for hypertension patients, the Centers for Medicare & Medicaid Services (CMS) has approved Medicare reimbursement for...
Read more
Novo Nordisk Abandons Kidney Disease Drug from $1.3 Billion Acquisition After Phase 3 Setback
Novo Nordisk has officially pulled the plug on ocedurenone, a promising kidney disease drug acquired for $1.3 billion from KBP...
Read more
